Losartan in Treating Pulmonary Fibrosis in Patients With Stage I, II, or III Non-Small Cell Lung Cancer
This study has been withdrawn prior to enrollment.
(Study concept was not approved by NCI. Study was never activated. No enrollment)
Sponsor:
University of South Florida
Collaborator:
Information provided by (Responsible Party):
University of South Florida
ClinicalTrials.gov Identifier:
NCT00880386
First received: April 10, 2009
Last updated: January 31, 2013
Last verified: January 2013
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
RATIONALE: Losartan potassium may be effective in treating pulmonary fibrosis caused by radiation therapy in patients with non-small cell lung cancer.
PURPOSE: This clinical trial is studying losartan to see how well it works in treating pulmonary fibrosis caused by radiation therapy in patients with stage I, stage II, or stage III non-small cell lung cancer.
| Condition | Intervention |
|---|---|
|
Dyspnea Lung Cancer Pulmonary Complications Radiation Fibrosis |
Drug: losartan potassium Other: questionnaire administration Procedure: breath test |
| Study Type: | Interventional |
| Study Design: | Primary Purpose: Supportive Care |
| Official Title: | A Pilot Project to Determine the Effect of Losartan (Cozaar) on Radiation-Induced Pulmonary Fibrosis in Patients With Non-Small Cell Lung Cancer |
Resource links provided by NLM:
Further study details as provided by University of South Florida:
Primary Outcome Measures:
- Change in carbon monoxide diffusing capacity (DLCO) at 6 months [ Designated as safety issue: No ]
Secondary Outcome Measures:
- Feasibility of losartan potassium as treatment for radiation-induced pulmonary fibrosis [ Designated as safety issue: No ]
- Pulmonary function measurements of FEV1 and FVC and dyspnea score at 6 months [ Designated as safety issue: No ]
| Enrollment: | 0 |
OBJECTIVES:
Primary
- To evaluate the effects of losartan potassium on the disease progression in patients with stage I-III non-small cell lung cancer and radiation-induced pulmonary fibrosis.
- To determine the feasibility of losartan potassium as a possible treatment for radiation-induced pulmonary fibrosis.
Secondary
- The evaluate the effects of losartan potassium on the degree of dyspnea, and lung function (FEV_1 and FVC) in these patients.
OUTLINE: This is a multicenter study.
Patients receive oral losartan potassium once daily for 6 months in the absence of disease progression or unacceptable toxicity.
Patients undergo assessment of pulmonary function (e.g., gas movement, lung capacity, and diffusion of gases) by spirometry and dyspnea by the Visual Analog Scale (VAS) at baseline and at weeks 12 and 24.
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Criteria
DISEASE CHARACTERISTICS:
Diagnosis of non-small cell lung cancer
- Stage I, II, IIIA, or IIIB disease
Diagnosis of radiation therapy-induced pulmonary fibrosis within 2 years of last radiation treatment
- Grade I-III disease as defined by NCI CTCAE v3.0
- Diagnosis and grading based on radiographic changes of ≥ grade 1, defined as minimal radiographic findings (or patchy or bibasilar changes) with estimated radiographic proportions of total lung volume < 25% (if fibrotic)
PATIENT CHARACTERISTICS:
- Not pregnant or nursing
- Negative pregnancy test
- Fertile patients must use effective contraception
- Not currently smoking or smoked within the past 6 months
- No baseline systolic blood pressure < 100 mm Hg
- No bilateral renal artery stenosis, hereditary or idiopathic angioedema, or uncontrolled hypotension
- No history of kidney failure or liver disease
- Able to attend clinic visits
- No allergy or allergic reaction to losartan potassium or any other angiotensin II receptor blocker
PRIOR CONCURRENT THERAPY:
- See Disease Characteristics
- More than 6 months since prior and no concurrent use of another angiotensin II receptor blocker (i.e., losartan potassium, valsartan, irbesartan, candesartan, cilexetil, eprosartan mesylate, or telmisartan)
- No history of lung transplant
- No prior pneumonectomy
- No concurrent lithium
Contacts and Locations More Information
Additional Information:
No publications provided
| Responsible Party: | University of South Florida |
| ClinicalTrials.gov Identifier: | NCT00880386 History of Changes |
| Other Study ID Numbers: | CDR0000637808, SCUSF-PILOT-0208, MCC-PILOT-0208 |
| Study First Received: | April 10, 2009 |
| Last Updated: | January 31, 2013 |
| Health Authority: | United States: Food and Drug Administration |
Keywords provided by University of South Florida:
|
dyspnea stage I non-small cell lung cancer stage II non-small cell lung cancer stage IIIA non-small cell lung cancer |
stage IIIB non-small cell lung cancer pulmonary complications radiation fibrosis |
Additional relevant MeSH terms:
|
Carcinoma, Non-Small-Cell Lung Dyspnea Fibrosis Lung Neoplasms Pulmonary Fibrosis Radiation Pneumonitis Carcinoma, Bronchogenic Bronchial Neoplasms Respiratory Tract Neoplasms Thoracic Neoplasms Neoplasms by Site Neoplasms Lung Diseases Respiratory Tract Diseases Respiration Disorders |
Signs and Symptoms, Respiratory Signs and Symptoms Pathologic Processes Lung Diseases, Interstitial Lung Injury Radiation Injuries Wounds and Injuries Losartan Anti-Arrhythmia Agents Cardiovascular Agents Therapeutic Uses Pharmacologic Actions Antihypertensive Agents Angiotensin II Type 1 Receptor Blockers Angiotensin Receptor Antagonists |
ClinicalTrials.gov processed this record on May 19, 2013